{"contentid": 488650, "importid": NaN, "name": "Entresto data disappoint at annual meeting of ACC", "introduction": "At the annual meeting of the American College of Cardiology (ACC), poor results for Novartis\u00e2\u0080\u0099 Entresto (sacubitril/valsartan) have disappointed.", "content": "<p>At the annual meeting of the American College of Cardiology (ACC), poor results for Novartis&rsquo; (NOVN: VX) Entresto (sacubitril/valsartan) have disappointed.</p>\n<p>Results from the&nbsp;LIFE study, sponsored by the US National Institutes of Health (NIH), show the combination drug could not improve on valsartan alone in treating severe heart failure patients with reduced ejection fraction (HFrEF).</p>\n<p>The Swiss firm presented the data on Monday at the event, which is being held virtually due to the pandemic.</p>\n<p>Data from the study show that, after six months of treatment, there was no difference in terms of the clinical outcome, with valsartan alone outperforming Entresto by some measures, including cases of hyperkalemia.</p>\n<p>The study has been evaluating the most severe heart failure patients, and the results follow on from a presentation earlier at the event of complete data from Novartis&rsquo; PARADISE-MI trial.</p>\n<p>That study has been testing Entresto as an option following heart failure, with an endpoint of death and heart failure events.</p>\n<p>While the treatment also missed the primary endpoints in that study, it did hit some secondary endpoints, raising the possibility of further development.</p>", "date": "2021-05-17 14:24:00", "meta_title": NaN, "meta_keywords": "Entresto, annual, meeting, data, results, study, disappoint, heart, failure, American, College, Cardiology, poor, sacubitril/valsartan, disappointed, show", "meta_description": "At the annual meeting of the American College of Cardiology (ACC), poor results for Novartis\u00e2\u0080\u0099 Entresto (sacubitril/valsartan) have disappointed.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-17 14:24:33", "updated": "2021-05-18 05:44:04", "access": NaN, "url": "https://www.thepharmaletter.com/article/entresto-data-disappoint-at-annual-meeting-of-aac", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "novartis_logo_big.jpg", "image2id": "novartis_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Cardio-vascular", "topic_tag": "ACC, Conferences, Drug Trial, Research", "geography_tag": "Switzerland, USA", "company_tag": "Novartis", "drug_tag": "Entresto", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-17 14:24:00"}